Candriam S.C.A. Alector, Inc. Transaction History

Candriam S.C.A.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	SELL	$5.85 - $9.84 $172,984 - $290,968	-29,570 Reduced 30.19%	68,368 $423,000
Q4 2022 Feb 13, 2023	BUY	$6.88 - $9.55 $40,076 - $55,628	5,825 Added 6.32%	97,938 $903,000
Q3 2022 Nov 10, 2022	BUY	$8.19 - $13.2 $754,405 - $1.22 Million	92,113 New	92,113 $871,000
Q2 2021 Jul 20, 2021	SELL	$15.5 - $22.48 $2.4 Million - $3.48 Million	-154,783 Closed	0 $0
Q4 2020 Jan 22, 2021	SELL	$9.4 - $16.7 $53,495 - $95,039	-5,691 Reduced 3.55%	154,783 $2.34 Million
Q3 2020 Oct 19, 2020	BUY	$10.54 - $24.96 $1.69 Million - $4.01 Million	160,474 New	160,474 $1.69 Million

168

57.8M

146K

90.8K

Ticker ALEC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 82,563,904
Market Cap $153M
Description
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis dise...

Get notified when there are updates to the investment portfolio of Candriam S.C.A., based on Form 13F filings with the SEC.

Stay updated on Candriam S.C.A. with notifications on news.